Showing results out of
Using machine learning to analyse the genetic factors behind early clinical trial termination, researchers find a link between genetic evidence and trial outcome.
SCIENCE & TECHNOLOGY2024
research-highlightsscience-technology
MSD joins as the latest partner in the Open Targets consortium, enhancing the initiative’s collaborative efforts in drug discovery.
EMBL ANNOUNCEMENTS2024
announcementsembl-announcements
A new tool for the interpretation of missense variation in humans – ProtVar – will help enable drug discovery.
SCIENCE & TECHNOLOGY2023
sciencescience-technologytechnology-and-innovation
Researchers create a network of interacting proteins – or interactome – to aid drug discovery.
2023
research-highlightsscience
Open Targets is using artificial intelligence and machine learning to identify and prioritise drug targets.
SCIENCE & TECHNOLOGY2023
sciencescience-technologytechnology-and-innovation
Open Targets announces that Genentech will become the seventh partner in the drug discovery and validation consortium.
2022
announcementsscience
Open Targets, a consortium focused on drug target identification, prioritisation, and validation, announced today that Pfizer has joined as a partner.
CONNECTIONS2022
announcementsconnectionsscience
No results found